Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 178Lung Neoplasms 56NSCLC 11Neoplasms 10Neoplasm Metastasis 9Brain Neoplasms 8Carcinoma 7Bronchial Neoplasms 5Thoracic Neoplasms 4Colorectal Neoplasms 4Respiratory Tract Neoplasms 3Respiratory Tract Diseases 3Neoplasms by Site 3Meningeal Carcinomatosis 3Lung Diseases 3Carcinoma, Squamous Cell 3Breast Neoplasms 3Adenocarcinoma of Lung 3Adenocarcinoma 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Noonan Syndrome 2Non Small Cell Lung Cancer Metastatic 2Neoplasms, Nerve Tissue 2Neoplasms by Histologic Type 2Carcinoma, Bronchogenic 2Triple Negative Breast Neoplasms 1

Interventions

osimertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
T790M Positive NSCLC Patients × osimertinib × Thoracic × Clear all
NCT03133234 2018-11-20

Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

AstraZeneca

Completed
47 enrolled
Thoracic

T790M Positive NSCLC Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡